EPIRUS Biopharmaceuticals, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported loss from operations of $13,929,000 against $3,026,000 a year ago. Loss before income taxes was $13,935,000 against $4,294,000 a year ago. Net loss was $13,935,000 against $4,278,000 a year ago. Basic and diluted loss per share was $1.28 against $18.05 a year ago.

For the nine months, the company reported loss from operations of $29,100,000 against $10,637,000 a year ago. Loss before income taxes was $31,427,000 against $13,038,000 a year ago. Net loss was $31,445,000 against $13,022,000 a year ago. Basic and diluted loss per share was $8.15 against $55.38 a year ago.